Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
NCT ID: NCT03527160
Last Updated: 2021-10-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
134 participants
OBSERVATIONAL
2018-04-23
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utility of NGAL to Diagnose AKI in Critically Ill Children
NCT03034876
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates
NCT02443389
Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI
NCT05114057
NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care
NCT02121470
Study of the Prediction of Acute Kidney Injury in Children Using Risk Stratification and Biomarkers
NCT01735162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving 3 or more days of an intravenous aminoglycoside or vancomycin
Exclusion Criteria
* Presence of an acute kidney injury prior to enrollment
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioPorto Diagnostics
INDUSTRY
Children's Hospital Medical Center, Cincinnati
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's of Alabama
Birmingham, Alabama, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIN001 - NINJA NGAL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.